Sono stati pubblicati i risultati della Joint Transnational Call (JTC) 2022.

14 i consorzi selezionati che riceveranno un finanziamento complessivo pari a €15,1 milioni per sviluppare nuovi approcci traslazionali affrontando le sfide dei tumori difficili da trattare.

I progetti si occuperanno del rilevamento precoce dei tumori attraverso strumenti innovativi, implementando l’efficacia di rilevamento, diagnosi, prognosi e trattamento dei tumori, attraverso collaborazioni multidisciplinari e multiprofessionali.

I PROGETTI SELEZIONATI

1. ANGELA – Early detection of esophageal squamous cell carcinoma with the Cytosponge coupled with molecular biomarkers and machine learning
2. BileCanMet – Precision medicine in cholangiocarcinoma: accurate tools for early detection and identification of PRMT5 as a novel pharmacological target
3. CAR4PDAC – Hijacking stroma antigens for CAR-T cell immunotherapy of PDAC
4. iCC-Strat – Risk stratification and subtyping of intrahepatic cholangiocarcinoma for early detection of recurrence and response to immuno-therapy
5. IdeaTMEHCC – Identification of therapeutic targets using HCC DErived organoid Augmented with TME components.
6. MATTO-GBM – Multimodality Artificial intelligence open-source Tools for Radiation Treatment Optimization in patients with Glioblastoma
7. NK-4-GBM – Metabolically optimised NK cell therapies for Glioblastoma
8. PaCaNano – Development of a pancreatic cancer drug-nanocarrier system selectively targeting tumour cells and tumour stroma to overcome treatment failure
9. PANC-P53 – Innovative peptide- and RNA-based strategies to modulate p53 for pancreatic cancer therapy
10. PLASTIG – Tackling tumor heterogeneity and PLASTIcity as resistance mechanisms in Glioblastoma
11. PRECEDENCE – Genotype matched therapies in intrahepatic cholangiocarcinoma: a multi-pronged strategy for improving efficacy and combating resistance.
12. ReachGLIO – Reaching the heterogeneous vascular landscape of glioblastoma with multifunctional nanomedicines.
13. SIMMBAP – Systemic immunological determinants of tumor evolution and therapy response in BRCA-mutated pancreatic cancer
14. T-Plex EAC – T-Plex-Capture: Isolation of neoantigen-specific CD8+ T cell receptors for patient-specific immunotherapy in esophageal adenocarcinoma (EAC)

Per maggiori dettagli, si prega di seguire il seguente LINK.

Per maggiori informazioni sul 3 bando lanciato da TRASCAN, si prega di cliccare il seguente LINK.